ClinConnect ClinConnect Logo
Search / Trial NCT03748381

Comparison of 2 Diffractive Trifocal IOLs

Launched by PRIM. PROF. DR. OLIVER FINDL, MBA · Nov 19, 2018

Trial Information

Current as of April 25, 2025

Unknown status

Keywords

Cataract Surgery Trifocal Iol

ClinConnect Summary

Spectacle independence is a central aim in modern cataract surgery. Although bilateral monofocal IOL implantation, aiming for emmetropia or low myopia, leads to high levels of patient satisfaction in distance vision, spectacle dependence for reading and other near vision tasks is the usual result.

The option commonly used to achieve spectacle independence are multifocal intraocular lenses (IOLs). Multifocal IOLs either use a refractive or diffractive design or a combination of both or segmented asymmetric optics. The principal of the refractive design is based on changing the route of ligh...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age-related cataract
  • Scheduled for bilateral cataract extraction
  • Motivated to be less spectacle dependant
  • Age 21 and older
  • Corneal astigmatism ≤ 1.5 D (Keratometry, IOL Master 700)
  • written informed consent prior to recruitment
  • Exclusion Criteria:
  • Pregnancy (pregnancy test will be taken pre-operatively in women of reproductive age)
  • Retinitis pigmentosa
  • Chronic uveitis
  • Amblyopia
  • Pupil decentration \> 1mm center shift
  • preceded retinal surgery
  • preceded Laser-in-situ-Keratomileusis (LASIK)
  • Any ophthalmic abnormality that could compromise visual function or the measurements

About Prim. Prof. Dr. Oliver Findl, Mba

Prim. Prof. Dr. Oliver Findl, MBA, is a distinguished clinical trial sponsor renowned for his expertise in ophthalmology and a strong commitment to advancing medical research. With a robust academic background and extensive clinical experience, he leads innovative studies aimed at improving patient outcomes and fostering breakthroughs in eye care. Dr. Findl combines his clinical acumen with a strategic approach to trial management, ensuring rigorous adherence to ethical standards and regulatory compliance. His dedication to collaboration and excellence positions him as a trusted partner in the development of transformative therapies.

Locations

Vienna, , Austria

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials